Document Detail


Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.
MedLine Citation:
PMID:  22257975     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause 'sleepiness' or 'sedation', this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6 weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20 min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2 ± 0.8 min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3 ± 0.8 min) than in those without subjective sleepiness (14.9 ± 0.7 min), a short sleep latency was not necessarily associated with subjective sleepiness. In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness.
Authors:
Michael Kluge; Hubertus Himmerich; Peter M Wehmeier; Christine Rummel-Kluge; Mira Dalal; Dunja Hinze-Selch; Thomas Kraus; Ralf W Dittmann; Thomas Pollmächer; Andreas Schuld
Related Documents :
15290325 - Archaeal elongation factor 1alpha from sulfolobus solfataricus interacts with the eubac...
10389495 - The role of peripheral and central visual information for the directional control of ma...
5359625 - Reinforcement of eye movement with concurrent schedules.
20333405 - Psychomotor control in a virtual laparoscopic surgery training environment: gaze contro...
9468055 - Piezoelectric response of scleral collagen.
8498395 - Sleep apnea in male patients with the fibromyalgia syndrome.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-01-16
Journal Detail:
Title:  Schizophrenia research     Volume:  135     ISSN:  1573-2509     ISO Abbreviation:  Schizophr. Res.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-24     Completed Date:  2012-06-26     Revised Date:  2012-08-22    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  123-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Affiliation:
Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany. Michael.Kluge@medizin.uni-leipzig.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Analysis of Variance
Antipsychotic Agents / therapeutic use*
Benzodiazepines / therapeutic use*
Clozapine / therapeutic use*
Disorders of Excessive Somnolence / drug therapy*,  etiology
Double-Blind Method
Female
Humans
Male
Middle Aged
Polysomnography
Psychiatric Status Rating Scales
Reaction Time / drug effects
Schizophrenia / complications,  drug therapy*
Sleep Stages / drug effects
Statistics as Topic
Time Factors
Young Adult
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Complete Paraplegia Resulting from Surfer's Myelopathy.
Next Document:  Indium Tin Oxide devices for amperometric detection of vesicular release by single cells.